Share This Article:

Evaluation of Biological Effects of Nanosystems of Directed Transport in Experiments in Vivo and Their Application Possibilities in Anti-Tumor Therapy

Full-Text HTML Download Download as PDF (Size:517KB) PP. 145-153
DOI: 10.4236/anp.2013.22023    3,565 Downloads   6,067 Views  


The aim of the investigations was to evaluate benefits of the directed transport system - a nanocomposite, based on cisplatin and magnetite combined with local action of constant magnetic field on the tumor, in experiments in vivo in animals with transplantable Guerin carcinoma. Animals were divided into 5 groups according to the type of agent. We showed that nanocomposite in combination with static magnetic field exercises more prominent anti-tumor activity than cisplatin alone. It should be noted that regardless of the therapeutic agent, in Guerin carcinoma we observed

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Chekhun, V. , Naleskina, L. , Polishchuk, L. , Todor, I. , Demash, D. and Lukianova, N. (2013) Evaluation of Biological Effects of Nanosystems of Directed Transport in Experiments in Vivo and Their Application Possibilities in Anti-Tumor Therapy. Advances in Nanoparticles, 2, 145-153. doi: 10.4236/anp.2013.22023.


[1] S. K. Sahoo, S. Parveen and J. J. Panda, “The Present and Future of Nanotechnology in Human Health Care,” Nanomedicine, Vol. 3, No. 1, 2007, pp. 20-31. doi:10.1016/j.nano.2006.11.008
[2] X. Dong and R. J. Mumper, “Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress,” Nanomedicine, Vol. 5, No. 4, 2010, pp. 597-615.
[3] X. Chi, D. Huang D, Z. Zhao, Z. Zhou, Z. Yin and J. Gao, “Nanoprobes for in Vitro Diagnostics of Cancer and Infectious Diseases,” Nanomaterials, Vol. 33, No. 1, 2012, pp.189-206.
[4] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”, International Journal of Cancer, Vol. 127, No. 12, 2010, pp. 2893-2917. doi:10.1002/ijc.25516
[5] M. Chadambram, R. Manavalan and K. Kathiresan, “Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations,” Journal of Pharmacy and Pharmaceutical Sciences, Vol. 14, No.1, 2011, pp. 67-77.
[6] O. P. Singh and R. M. Nehru, “Nanotechnology and Cancer Treatment,” Asian Journal of Experimental Sciences, Vol. 22, No. 2, 2008, p. 6.
[7] R. Sinha, G. J. Kim, S. Nie and D. M. Shin, “Nanotechnology in Cancer Therapeutics: Bioconjugated Nanoparticles for Drug Delivery,” Molecular Cancer Therapeutics, Vol. 5, No. 8, 2006, pp. 1909-1917. doi:10.1158/1535-7163.MCT-06-0141
[8] B. Haley and E. Frenkel, “Nanoparticles for Drug Delivery in Cancer Treatment,” Urologic Oncology, Vol. 26, No. 1, 2008, pp. 57-64. doi:10.1016/j.urolonc.2007.03.015
[9] V. F. Chekhun, “Role of Innovative Technologies in Solving of Oncological Problems,” Visnyk NAS Ukraine, No. 9, 2008, pp. 38-42.
[10] A. P. Naga and A. Siddiqui, “Nanomedical Platform for Drug Delivery,” Journal of Nanomedicine Nanotechnology, Vol. 2, 2011, p. 122.
[11] E. Gullotti and Y. Yeo, “Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery,” Molecular Pharmaceutics, Vol. 6, No. 4, 2009, pp. 1041-1051. doi:10.1021/mp900090
[12] H. S. Choi and J. V. Frangioni, “Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation,” Molecular Imaging, Vol. 9, No. 6, 2010, pp. 291-310.
[13] B. Szalay, E. Tatrai, G. Nyiro, V. Tunde and G. Dura, “Potential Toxic Effects of Iron Oxide Nanoparticles in in Vivo and in Vitro Experiments,” Journal of Applied Toxicology, Vol. 32, No. 6, 2012, pp. 446-453. doi:10.1002/jat.1779
[14] UA Patent 99211, P. P. Horbyk, “Nanocapsule with Nanorobot Functions,” 2012.
[15] N. Y. Lukianova, N. V. Rusetskaya, L. A. Naleskina and V. F. Chekhun, “Some Mechanisms of Nanocomposit Action on Sensitive and Resistant MCF-7 Cells,” Materials of 7th CIS Oncologists’ and Radiologisits’ Meeting, Kazakhstan, 2012, p. 499.
[16] M. Kates, “Techniques of Lipidology. Isolation, Analysis and Identification of Lipids,” 1975.
[17] V. E. Vaskovsky and T. A. Terekhova, “HPTLC of Phospholipid Mixtures Containing Phosphatidylglycerol,” Journal of High Resolution Chromatography & Chromatography Communications, Vol. 2, No. 2, 1979, pp. 671 672. doi:10.1002/jhrc.1240021107
[18] N. Todor, N. Yu. Lukianova and V. F. Chekhun, “The Lipid Content of Cisplatin and Doxorubicin-Resistant MCF-7 Human Breast Cancer Cells,” Experimental Oncology, Vol. 34, No. 2, 2012, pp. 97-100.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.